AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts
Article excerpt
Highlighted: the sentence this signal was extracted from
$1 billion investment will grow AstraZeneca's workforce in Massachusetts by over 50% and deliver next-generation medicines. AstraZeneca today announced the opening of its newest global strategic research and development (R&D) centre, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on the Company's existing presence in Cambridge and Boston and places its scientists at the heart of one of the world's most innovative life sciences ecosystems. Together with its site for genomic medicine at 100 Binney Street, The AstraZeneca R&D Center Kendall Square will be home to nearly 2,000 world-class researchers and scientists who will accelerate the Company's oncology, cell therapy, chronic disease and rare disease pipeline to deliver transformative medicines of the future. The 570,000 square foot, 18 story site at 290 Binney Street is designed to enhance collaboration and was built with the highest standards of sustainable design to minimize our impact on the planet. The R&D centre includes ten floors of interconnecting laboratories to allow a flow of seamless science enabled by cutting-edge technologies that integrate robotics, continuous automation, and agentic AI. Leading experts will deliver novel treatments from our pipeline to treat people struggling to live with diseases such as COPD, obesity and metabolic disease, breast cancer and rare...
Keep reading with a free account
The rest of this article, and every signal for AstraZeneca, is in your free account.
